The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.
The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.
“The norm in the United States has been for most pharmaceutical manufacturers to increase prices year after year—even accounting for the discounts they give insurers, and even for drugs that already sit at the top of the chart of spending for drugs in the US,” said David Rind, MD, ICER’s chief medical officer, in a statement, adding that the new report can help provide policy makers with an independent approach to determining whether price increases can be supported by new data.
In its analysis, ICER ranked the top 100 drugs by US sales revenue, and evaluated whether their prices, after accounting for rebates and concessions, were more than twice the level of growth in the medical consumer price index from 2017 to 2018. The ICER team then evaluated whether any relevant new evidence had emerged for these drugs over the past 3 years that could support a price increase.
They found that there were 7 drugs that had price hikes without adequate data to support the new costs, and the product that had the price increase with the greatest impact on US spending was the brand-name adalimumab, Humira.
With its 19.1% increase in its wholesale acquisition cost (WAC) from the end of 2016 to the end of 2018, and an estimated 15.9% net price increase over the same period, ICER estimates that increases to Humira’s price cost the United States $1857 million between 2017 and 2018.
The drug whose price hikes had the second greatest impact on spending was brand-name rituximab, Rituxan. With a 17.0% increase in WAC and a 23.6% estimated increase in net price, Rituxan was responsible for a US spending impact of $806 million.
A third biologic with approved biosimilars that saw its prices rise without support was brand-name pegfilgrastim, Neulasta. Pegfilgrastim came in fifth in terms of its impact on US spending, with a 14.6% WAC increase, an estimated 13.4% net price increase, and a $489 million increase in spending.
The other drugs identified by ICER as having unsupported price increases were pregabalin (Lyrica), tenofovir disoproxil fumarate (Truvada), tadalafil (Cialis), and dimethyl fumarate (Tecfidera).
While Humira has 4 FDA-approved biosimilars, no products are set to launch in the US market until 2023 as a result of patent settlements between Humira-maker AbbVie and biosimilar developers. In the case of Rituxan, 2 products have been approved by the FDA, but no launch date has been disclosed for either one. Neulasta currently faces US market competition from Coherus BioScience’s Udenyca and Mylan and Biocon’s Fulphila.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.